Harvard cancer researcher struggles to cope with grant disruptions, fears for her team's future.
In the world of cancer research, there are few things more precious than a multi-year grant from the National Institutes of Health (NIH). The funding is crucial for a project like Dr. Joan Brugge's, where her team analyzes thousands of breast tissue samples to find new ways to prevent breast cancer.
Last year, the Trump administration froze all NIH grants at Harvard Medical School, citing concerns about campus antisemitism. The move had a devastating impact on Brugge's lab, with seven researchers losing their jobs and three more taking leave due to uncertainty over their future. The lab lost funding for its research, leaving many of its employees without steady income.
Despite the challenges, Brugge remains committed to her work. She has been searching for private funding sources and recently managed to reinstate two positions. However, job applicants are wary about applying to a lab that is still reeling from the grant disruption.
Across the United States, the future of federal funding for cancer research is uncertain. The Trump administration has proposed cutting the NIH budget by nearly 40% in the 2026 fiscal year, which could have a significant impact on treatment options for patients.
Cancer advocates argue that reductions in research funding will have direct consequences for patients, particularly if it leads to fewer new drugs or treatments being developed. A recent study found that more than half of NIH-funded drugs would not have been developed without the agency's support.
For Brugge and her team, the uncertainty is a constant source of anxiety. With their current funding set to end in August, they are racing against time to secure additional funding sources. The lab has lost several employees, including one who moved to Switzerland for further education, raising concerns about the long-term viability of cancer research in the US.
As Brugge looks at the pink-lidded jars containing breast tissue samples, she still sees promise. However, the existential threat of ongoing grant disruptions and funding uncertainty hangs over her lab like a dark cloud. Whether they can overcome these challenges remains to be seen, but for now, the future of cancer research in the US is far from secure.
In the world of cancer research, there are few things more precious than a multi-year grant from the National Institutes of Health (NIH). The funding is crucial for a project like Dr. Joan Brugge's, where her team analyzes thousands of breast tissue samples to find new ways to prevent breast cancer.
Last year, the Trump administration froze all NIH grants at Harvard Medical School, citing concerns about campus antisemitism. The move had a devastating impact on Brugge's lab, with seven researchers losing their jobs and three more taking leave due to uncertainty over their future. The lab lost funding for its research, leaving many of its employees without steady income.
Despite the challenges, Brugge remains committed to her work. She has been searching for private funding sources and recently managed to reinstate two positions. However, job applicants are wary about applying to a lab that is still reeling from the grant disruption.
Across the United States, the future of federal funding for cancer research is uncertain. The Trump administration has proposed cutting the NIH budget by nearly 40% in the 2026 fiscal year, which could have a significant impact on treatment options for patients.
Cancer advocates argue that reductions in research funding will have direct consequences for patients, particularly if it leads to fewer new drugs or treatments being developed. A recent study found that more than half of NIH-funded drugs would not have been developed without the agency's support.
For Brugge and her team, the uncertainty is a constant source of anxiety. With their current funding set to end in August, they are racing against time to secure additional funding sources. The lab has lost several employees, including one who moved to Switzerland for further education, raising concerns about the long-term viability of cancer research in the US.
As Brugge looks at the pink-lidded jars containing breast tissue samples, she still sees promise. However, the existential threat of ongoing grant disruptions and funding uncertainty hangs over her lab like a dark cloud. Whether they can overcome these challenges remains to be seen, but for now, the future of cancer research in the US is far from secure.